+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

World Hemoglobinopathies Market - Opportunities and Forecasts, 2017 - 2023

  • ID: 3773143
  • Report
  • September 2019
  • Region: Global
  • Allied Analytics LLP
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
Hemoglobinopathy is a genetic disorder that causes structural abnormalities in hemoglobin molecules, particularly defective globin chains. Hemoglobinopathies are inherited single-gene disorders of which sickle cell disease is the most common kind. There is a high prevalence of Hemoglobinopathies in Africa, Southeast Asia and the Mediterranean basin. If left untreated, critical cases of hemoglobinopathies lead to anemia, organ dysfunction or death. Gel electrophoresis and complete blood count are used as diagnostic tests to determine the presence of hemoglobinopathies. The disease does not have a permanent cure; this has resulted in a growing demand for new product innovations in the pharmaceutical sector. Additionally, the high prevalence of the disease and the national control program are driving the need for drug therapy in developing economies. Alnylam Pharmaceuticals, Gamilda Cell, Sangamo Biosciences, Cancer Therapeutics CRC Pty Ltd and Biogen Idec are some of the key players in this market. These companies have invested huge sums of money in research and development of hemoglobinopathies to develop a permanent cure for this disease. NiCord, ZFP and ALN-TMP are some of the current products available in the market. Companies have adopted the strategy of collaboration and licensing to supplement their research activities.

Global hemoglobinopathies market is segmented on the basis therapeutics and geography. The therapeutic segment includes various drugs such as NiCord, ZFP Transcription Factors, ALN-TMP, Drug Targeting PRMT5 and Drug Targeting Protein Arginine Methyltransferase 5. ALN-TMP is a subcutaneous RNAi therapeutic that targets Tmprss6 and is used in the treatment of ß-thalassemia. NiCord®, based on the novel NAM technology, is a potential solution for a number of diseases such as thalassemia, sickle cell disease, hematological malignancies, severe rare genetic metabolic diseases and autoimmune diseases. Geographically, the global hemoglobinopathies market is segmented into North America, Europe, Asia-Pacific and LAMEA. Africa is the leading market for these drugs due to the high prevalence of hemoglobinopathies in the region.

KEY BENEFITS

The report provides an overview of the global hemoglobinopathies market, which includes drivers, restraints and opportunities to help professionals better understand market behavior
Detailed information regarding R&D activities, pipeline research, partnerships, licensing and collaborations in the global hemoglobinopathies market would be informative for professionals in the corporate sector
Pin-point analysis of geographic segments would help stakeholders identify opportunities for growth within the global hemoglobinopathies market
Porter’s Five Forces analysis examines the competitive structure of the global hemoglobinopathies market and would assist market strategists in their decision making process

KEY MARKET SEGMENTS

The global hemoglobinopathies market is segmented into two major categories: pipeline therapeutics and geography.

MARKET BY PIPELINE THERAPEUTICS

NiCord
ZFP Transcription Factors
ALN-TMP
Drug Targeting PRMT5
Drug Targeting Protein Arginine Methyltransferase 5

MARKET BY GEOGRAPHY

North America
Europe
Asia-Pacific
LAMEA

Note: Product cover images may vary from those shown
2 of 2

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll